Dou et al. demonstrated that CKD patients with stages 3–5 showed strong serum AHR-activating potential and upregulated mRNA levels of CYP1A1 and AHR repressor in whole blood compared to serum from healthy controls (Dou et al., 2018). This evidence concerns the gene CYP1A1 and chronic kidney disease.